{
    "nctId": "NCT02396420",
    "officialTitle": "Phase II, Single Center, Single Arm, Open Label Investigation of Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams",
    "inclusionCriteria": "* Patient has provided signed informed consent\n* Patient is aged greater than or equal to 40 and less than or equal to 89 years of age\n* Patient has a prostate size between 90g and 200g, as determined by MRI\n* Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment\n* Patient has an IPSS score of at least 13 at baseline\n* Patient is either: refractory to medical treatment, contraindicated to medical treatment, OR refuses medical treatment\n* Patient either: refuses surgical treatment OR is contraindicated for surgical treatment\n* Patient meets ONE of the following criteria: baseline PSA \\< 4.0ng/mL (no prostate biopsy required) OR baseline PSA \\>/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy) within the prior 12 months\n* Must be MALE\n* Must have minimum age of 40 Years\n* Must have maximum age of 89 Years",
    "exclusionCriteria": "* History of prostate, bladder, or rectal cancer\n* History of transurethral resection of the prostate (TURP), open prostate surgery, or radiofrequency or microwave therapies\n* History of open bladder, rectosigmoid colon, or other pelvic surgery\n* Patient is unwilling to discontinue alpha blockers 1 month after study treatment\n* Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment\n* Neurogenic bladder or other neurologic disorder impacting bladder function such as Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes\n* Any other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia\n* Active prostatitis or urinary tract infection\n* Cystolithiasis within the past 3 months\n* Serum creatinine \\> 1.7mg/dL\n* Inability to discontinue oral anticoagulant 2-5 days prior to study treatment\n* Coagulation disturbances not normalized by medical treatment\n* Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated\n* Gelatin allergy\n* Known severe peripheral vascular disease or major iliac arterial occlusive disease\n* Interest in future fertility\n* Clinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression\n* Other condition that the Investigator believes puts the patient at risk for a complication during the procedure"
}